Thursday, October 15, 2026
ExploreSearch
Finance Via News

Corporate Partnerships

3 articles

NVIDIA's BioNeMo Becomes Pharma's Shared AI Backbone as Platform Race With Specialized Rivals Heats Up

NVIDIA's BioNeMo Becomes Pharma's Shared AI Backbone as Platform Race With Specialized Rivals Heats Up

NVIDIA's BioNeMo platform is anchoring AI drug discovery partnerships with Eli Lilly and Thermo Fisher, cementing a scale-first infrastructure play. Novo Nordisk's 24.9% 30-day stock surge and strong Q1 2026 earnings reinforce market conviction in AI-powered pipelines. But purpose-built challengers—Natera, Owkin, Boltz Lab—are mounting a direct bid for the same enterprise R&D budgets.

LM Salvado•
Corning Stock Surges 137.4% YTD as NVIDIA Partnership Drives AI Data Center Expansion

Corning Stock Surges 137.4% YTD as NVIDIA Partnership Drives AI Data Center Expansion

Corning shares have risen 137.4% year to date, powered by an expanded long-term partnership with NVIDIA and surging demand for fiber optic components in AI data centers. The company plans three new manufacturing facilities to meet buildout requirements. Enterprise AI adoption is accelerating the need for high-capacity optical interconnects.

LM Salvado•
NVIDIA BioNeMo Wins Thermo Fisher, Eli Lilly as AI Drug Discovery Partners

NVIDIA BioNeMo Wins Thermo Fisher, Eli Lilly as AI Drug Discovery Partners

NVIDIA secured partnerships with Thermo Fisher and Eli Lilly for its BioNeMo platform as specialized biological AI models compete against general-purpose systems in early 2026. Multiple AI platforms from Basecamp Research, Boltz Lab, Owkin, and Edison Scientific launched simultaneously, marking a shift toward purpose-built foundation models for pharmaceutical R&D.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com